Nexalin Technology Inc. (NASDAQ: NXL) announced that the U.S. House of Representatives passed appropriations bill language directing the Department of Veterans Affairs to support additional research into non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant traumatic brain injury.

The House passed the Fiscal Year 2027 Military Construction, Veterans Affairs, and Related Agencies Appropriations bill in a 400-15 vote. The accompanying report language encourages the VA to evaluate the safety, efficacy, and clinical applications of non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant TBI.

The bill includes $945 million for VA Medical Research. The neurostimulation directive was among a limited number of Congressional directives for this account, according to the press release.

Nexalin's Nexalin America division advocated for the legislative language. The company stated the provision aligns with its ongoing clinical study at UC San Diego evaluating its Deep Intracranial Frequency Stimulation technology for traumatic brain injury treatment.

"For Congress to specifically direct and encourage the VA to support research evaluating the safety, efficacy and clinical applications of non-invasive deep brain techniques for treatment-resistant TBI is, in our view, a strong validation of the category Nexalin is helping pioneer," said Mark White, chief executive officer of Nexalin Technology.

The bill is expected to proceed to a House-Senate conference following passage of comparable legislation from the Senate. Nexalin's Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, Oman and Israel.

The information is based on a company press release.